ArticlePharmacoEconomics2022
The Relevance of Including Future Healthcare Costs in Cost-Effectiveness Threshold Calculations for the UK NHS.
Article in PharmacoEconomics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- The health economics of insulin therapy: How do we address the rising demands, costs, inequalities and barriers to achieving optimal outcomes.Diabetes, obesity & metabolism · 2025Article
- A Framework for the Fair Pricing of Medicines.PharmacoEconomics · 2024Article
- Context-Specific Estimation of Future Unrelated Medical Costs and Their Impact on Cost-Effectiveness Analyses.PharmacoEconomics · 2023Article
- 10 Years of AMNOG: What is the Willingness-to-Pay for Pharmaceuticals in Germany?Applied health economics and health policy · 2023Article
- The Value of Health in a Cost-Effectiveness Analysis: Theory Versus Practice.PharmacoEconomics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveThe supply-side threshold for the UK National Health Service has been empirically estimated as the marginal returns to healthcare spending on health outcomes. These estimates implicitly exclude future healthcare costs, which is inconsistent with the objective of making the most efficient use of healthcare resources. This paper illustrates how empirical estimates of the threshold within healthcare can be adjusted to account for future healthcare costs.
methodsUsing cause-deleted life tables and previous work on future costs in England and Wales, we illustrate how such estimates can be adjusted.
resultsWhile the effect of including future healthcare costs can have substantial effects on incremental cost-effectiveness ratios of specific life-extending interventions, we find that including future costs has relatively little impact (an increase of £743 per quality-adjusted life-year) on the threshold estimate.
conclusionsFor some life-extending interventions the impact of including future costs on whether an intervention is deemed cost effective may be considerable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.